d-tartrate (2-) | 3715-17-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: d-tartrate (2-)
• 英文别名: D(-)-tartrate；L-tartrate；tartrate；[R-(R*, R*)]-2,3-dihydroxybutanedioate；(2R,3R)-2,3-dihydroxybutanedioate；(R,R)-tartrate
• CAS: 3715-17-1
• 化学式: C₄H₄O₆
• 分子量: 148.072
• InChiKey: FEWJPZIEWOKRBE-JCYAYHJZSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  d-tartrate (2-) 生成 triphenylarsonium bis(methoxycarbonyl)methylide
  参考文献：
  名称：

  HOOD, J. N. C.;LLOYD, D.;MACDONALD, W. A.;SHEPHERD, T. M., TETRAHEDRON, 1982, 38, N 22, 3355-3358

  摘要：

  DOI：
• 作为产物：
  描述：

  nickel (II) d-tartrate 以 水 为溶剂， 生成 镍 、 d-tartrate (2-)
  参考文献：
  名称：

  Wu, C.-K.; Hsue, K.-H., 1965, vol. 31, p. 58 - 63

  摘要：

  DOI：
• 作为试剂：
  描述：

  (E)-4-methyl-pent-2-en-1-ol 在 d-tartrate (2-) 作用下， 生成 (2S,3S)-2,3-epoxy-4-methyl-1-pentanol
  参考文献：
  名称：

  轻松进行多烯大环内酯全合成；roflamycoin的主要手性部分

  摘要：

  制备了四块分别标记为A，B，D和E的Roflamycoin，分别对应于该天然产品中11个手性中心中的10个。

  DOI：

  10.1016/s0040-4039(00)85073-x

文献信息

• <i>In vivo</i> phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents
  作者：Liming Shao、Una C. Campbell、Q. Kevin Fang、Noel A. Powell、John E. Campbell、Philip G. Jones、Taleen Hanania、Vadim Alexandrov、Irene Morganstern、Emily Sabath、Hua M. Zhong、Thomas H. Large、Kerry L. Spear

  DOI：10.1039/c6md00128a

  日期：——

  A mouse-based assay (SmartCube) was used for both screening and lead optimization of a novel antipsychotic.

  一种基于老鼠的检测方法（SmartCube）被用于一种新型抗精神病药物的筛选和首选优化。
• L-tartrate of trans-(-)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound and process for preparing the same
  申请人：Sumika Fine Chemicals Co., Ltd.

  公开号：US20020028944A1

  公开（公告）日：2002-03-07

  An L-tartrate of a trans-(−)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound, represented by the formula (I): 1 wherein R 1 is hydrogen atom, a substituted or unsubstituted, linear or branched alkyl group having 1 to 6 carbon atoms, or an aralkyl group having 7 to 12 carbon atoms. The L-tartrate of trans-(−)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound can be suitably used as an intermediate for pharmaceuticals such as paroxetine which is useful, for example, as an antidepressant.

  一种以式(I)所表示的反式-(−)-4-(4-氟苯基)-3-羟甲基哌啶化合物的L-酒石酸盐：其中R1是氢原子，具有1至6个碳原子的取代或未取代的直链或支链烷基，或具有7至12个碳原子的芳基烷基。反式-(−)-4-(4-氟苯基)-3-羟甲基哌啶化合物的L-酒石酸盐可适当用作制备药物的中间体，如帕罗西汀，例如作为抗抑郁剂。
• Nitrogen heterocyclic carboximidamide compounds
  申请人：McNeil Laboratories, Incorporated

  公开号：US04211867A1

  公开（公告）日：1980-07-08

  5-, 6- or 7-Membered fully saturated 1-azacarbocyclic-2-ylidene derivatives of guanidine having anti-secretory and hypoglycemic activities, and further useful for treatment of cardiovascular disease states.

  5、6或7成员完全饱和的1-氮杂环丙基脲衍生物具有抗分泌和降血糖活性，并且进一步用于治疗心血管疾病状态。
• Process for preparing 1-hydroxy-3-oxa-1,2,4,5-pentane tetracarboxylic
  申请人：Monsanto Company

  公开号：US05028723A1

  公开（公告）日：1991-07-02

  There is disclosed an improved process for preparing 1-hydroxy-3-oxa-1,2,4,5-pentane tetracarboxylic acid and 3,6-dioxa-1,2,4,5,7,8-octane hexacarboxylic acid wherein the reaction mixture has a solids concentration of above about 60%, by weight whereby the amount of by-product fumarate is reduced.

  本发明公开了一种改进的制备1-羟基-3-氧杂-1,2,4,5-戊烷四羧酸和3,6-二氧杂-1,2,4,5,7,8-辛烷六羧酸的方法，其中反应混合物的固体浓度高于约60%，重量，从而减少了副产物富马酸的量。
• 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake
  申请人：Boulet Louis Serge

  公开号：US20060014779A1

  公开（公告）日：2006-01-19

  There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from C 2 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 8 cycloalkyl and C 4 -C 8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2 , —CF 3 , —CN and —CONH 2 ; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3 -benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2 , nitro, acetyl, —CF 3 , —SCF 3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C 1 -C 4 alkyl; Z is selected from H, OR 3 or F, wherein R 3 is selected from H, C 1 -C 6 alkyl and phenyl C 1 -C 6 alkyl; R 1 and R 2 are each independently H or C 1 -C 4 alkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

  提供了一种化合物，其化学式为（I），其中A从—O—和—S—中选择；X从C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基中选择，每种基团均可选用最多3个取代基，每个取代基可独立地从氯，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0，1或2，—CF3，—CN和—CONH2中选择；Y从苯基，萘基，二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基，噻吩基，茚基，1,3-苯并二氧杂环基，苯并噻吩基，吲哚基和苯并呋喃基中选择，每种基团均可选用最多4个或在可能的情况下最多5个取代基，每个取代基可独立地从氯，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0，1或2，硝基，乙酰基，—CF3，—SCF3和氰基中选择；当Y为吲哚基时，它可以被一个N-取代基所取代，所述取代基从C1-C4烷基中选择；Z从H，OR3或F中选择，其中R3从H，C1-C6烷基和苯基C1-C6烷基中选择；R1和R2各自独立地为H或C1-C4烷基；但是，当Z为H时，Y可能不是可选取代的苯基或可选取代的萘基。